On April 19, 2023 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, reported the presentation of additional preclinical data on the Company’s casitas B-lineage lymphoma-B (CBL-B) program in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 (Press release, HotSpot Therapeutics, APR 19, 2023, View Source [SID1234630330]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We believe the targeting of CBL-B, a master regulator of immune cell activation, represents a promising therapeutic approach given preclinical data that indicated CBL-B’s ability to lower the threshold for both T cell and natural killer (NK) cell activation, which has the potential to drive benefit for patients with tumors that respond poorly or do not respond to standard-of-care immunotherapies," said Geraldine Harriman, Ph.D., Co-Founder and Chief Scientific Officer of HotSpot. "These data lend strong support to the ability of CBL-B inhibition to affect change to the tumor microenvironment through the enhancement of NK cell proliferation and activity. We look forward to continuing to advance HST-1011, our lead CBL-B inhibitor clinical candidate, through our ongoing Phase 1 clinical study in patients."
The presentation describes preclinical data for a HotSpot compound that is designed as a novel, allosteric, small molecule inhibitor of CBL-B E3 ubiquitin ligase activity:
In in vitro studies, HotSpot’s CBL-B inhibitor demonstrated an ability to increase the single-cell polyfunctionality of NK cells and to enhance the activation of NK cells, NK cell proliferation, and NK cell-mediated cytotoxic activity against K562 cells. Additionally, HotSpot’s CBL-B inhibitor enhanced NK cell function in tumor models in vivo. Collectively, we believe these data demonstrated that inhibition of CBL-B can enhance the effector function of NK cells and, in turn, promote NK cell-mediated killing of cancer cells.
About HST-1011
HST-1011 is an investigational orally bioavailable, selective, small molecule allosteric inhibitor of CBL-B, an E3 ubiquitin protein ligase critically involved in immune cell response. Because CBL-B functions as a master regulator of effector cell (T cell and natural killer cell) immunity, its inactivation removes its endogenous negative regulatory functions to substantially enhance anti-tumor immunity. Preclinical data has demonstrated HST-1011’s ability to bind to and inhibit a natural hotspot on CBL-B, yielding the activation and propagation of a targeted anti-tumor immune response. Enabled by HotSpot’s proprietary Smart Allostery platform, HST-1011 is designed with tight binding, low nanomolar potency, a slow dissociation rate from the target to enable sustained pharmacology, and greater selectivity for CBL-B relative to C-CBL.